# Pharmolix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmolix

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Total disclosed funding: $14M
- Latest round: Angel (Aug 14, 2024)
- Investors on record: 4

## About

Established in 2023 and based in Beijing, China, Pharmolix operates as a biopharmaceutical company that focused on the development and application of large models for the biopharmaceutical vertical. The company was incubated by Tsinghua University's Academy of Intelligent Industry Research (AIR). Dr. Mu Qiao, CTO, and co-founder of the company, received his Ph.D. in Computer Science and Engineering and M.S. in Statistics from Pennsylvania State University in 2012, and was the research leader of the Artificial Intelligence Platform Division at IBM Research - Almaden. In August 2024, the firm raised CNY 100 million in angel funding.

The company's self-developed prototype of ChatDD (Chat Drug Design), a conversational biopharmaceutical R&D assistant, is equipped with the capabilities of natural interaction, intelligent inspiration and tool invocation. Its products will serve all aspects of drug development, including early research projects, target discovery, molecular design optimization, clinical trial design, and drug repositioning.

The company generates revenue by providing basic model base for the biomedical vertical industry and conversational biomedical research and development assistant.

The company will use the angel funding to develop the conversational drug development assistant tool ChatDD and the biomedical multimodal big model.

## Funding rounds

- Angel, Aug 14, 2024, $14M — WestSummit Capital, Kexun Ruijin Capital, Dalton Venture
- Seed, Jul 3, 2023 — Triwise Capital

## Investors

- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Seed
- WestSummit Capital (https://capitalatlas.ai/funds/westsummit-capital) — Angel
- Kexun Ruijin Capital (https://capitalatlas.ai/funds/kexun-ruijin-capital) — Angel
- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Angel